Skip to main content

ChromaDex Corporation (CDXC)

NASDAQ: CDXC · IEX Real-Time Price · USD
6.36 -0.34 (-5.07%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap451.46M
Revenue (ttm)62.01M
Net Income (ttm)-23.26M
Shares Out67.99M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume393,642
Open6.83
Previous Close6.70
Day's Range6.30 - 6.87
52-Week Range4.36 - 23.66
Beta1.73
AnalystsStrong Buy
Price Target14.80 (+132.7%)
Est. Earnings DateNov 4, 2021

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of...

IndustryLife Sciences Tools & Services
CEORobert Fried
Employees110
Stock ExchangeNASDAQ
Ticker SymbolCDXC
Full Company Profile

Financial Performance

In 2020, ChromaDex's revenue was $59.26 million, an increase of 28.01% compared to the previous year's $46.29 million. Losses were -$19.93 million, -38.02% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 14.80, which is an increase of 132.70% from the latest price.

Price Target
$14.80
(132.70% upside)
Analyst Consensus: Strong Buy

News

ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results ...

3 days ago - Business Wire

ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #cdxc--ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Heal...

2 weeks ago - Business Wire

ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChinaCrossBorder--ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to ...

2 weeks ago - Business Wire

ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Progra...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #nicotinamideriboside--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical ...

3 weeks ago - Business Wire

Why ChromaDex Stock Is Sinking Today

The company lost a key patent infringement lawsuit but plans to appeal the court decision.

1 month ago - The Motley Fool

Why Are ChromaDex Shares Trading Lower On Wednesday?

ChromaDex Corp (NASDAQ: CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by the U.S. District Court for the District of Delaware in a paten...

1 month ago - Benzinga

ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Inf...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ)...

1 month ago - Business Wire

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 11.11% and 7.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ChromaDex Corporation Reports Second Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021. Second Quarter 2021 and Recent Highlights Total net sale...

2 months ago - Business Wire

Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results fo...

2 months ago - Business Wire

CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH FOUR HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMART

ChromaDex Corp. (NASDAQ: CDXC) participated in a virtual presentation at the Benzinga Small Cap Conference in May 2021. ChromaDex CEO Rob Fried also presented on a panel discussing "Investing in Longevi...

3 months ago - Benzinga

ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented...

4 months ago - Business Wire

Why ChromaDex Stock Is Jumping Today

The company's flagship product was launched in Walmart stores across the U.S.

4 months ago - The Motley Fool

ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores

ChromaDex Corp (NASDAQ: CDXC) has launched its flagship consumer product Tru Niagen in Walmart Inc (NYSE: WMT), available in 3,800 stores across the U.S. The NAD+ booster will be offered to Walmart cust...

Other symbols:WMT
4 months ago - Benzinga

ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen® in Walmart, available in 3,800 stores across t...

4 months ago - Business Wire

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

ChromaDex Corporation Reports First Quarter 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 mil...

5 months ago - Business Wire

ChromaDex and Ro Partner for New Product Development

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology compan...

5 months ago - Business Wire

ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for ...

5 months ago - Business Wire

ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in p...

5 months ago - Business Wire

ChromaDex Appoints Fadi Karam as Chief Marketing Officer

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer...

5 months ago - Business Wire

ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® ni...

6 months ago - Business Wire

ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...

6 months ago - Business Wire

Is the Options Market Predicting a Spike in ChromaDex (CDXC) Stock?

Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research